ArticleColloids and surfaces. B, Biointerfaces2017
Contribution of Kupffer cells to liposome accumulation in the liver.
Article in Colloids and surfaces. B, Biointerfaces, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Targeted Nanoparticle Delivery CRISPR/Cas9: overcoming biological barriers, enhancing stability, and improving therapeutic precision.International journal of pharmaceutics: X · 2026Review
- A Strategic Formulation to Enhance the Safety and Anti-Hyperlipidaemic Activity of Simvastatin: Prototype Development.AAPS PharmSciTech · 2026Article
- Mathematical Modeling of Liver Metabolic Activity Under Ex Vivo Conditions upon Exposure to Magnetic Nanoparticles.Biomedicines · 2026Article
- Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- A Biomimetic Micro-Nano System Maximizing 'Active Transport and Retention' Effect in Solid Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Nanoparticle approaches for hepatitis therapy and clinical translation.Discover nano · 2026Review
- Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.Pharmaceutical nanotechnology · 2026Article
- Lipid-Based Nanocarriers for Curcumin Delivery: A Promising Strategy in The Management of Inflammatory Diseases.International journal of nanomedicine · 2026Review
- The efficacy of oligonucleotide-based gene therapeutics in gene silencing.Theranostics · 2026Review
- A multimodal approach to assess a liposomal carrier's biodistribution, stability, and clearance.Photoacoustics · 2025Article
- Fe(III)-Based Nanomicelles for Magnetic Resonance Imaging of Colorectal Cancer with Hepatic Metastasis.Journal of functional biomaterials · 2025Article
- Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver research (Beijing, China) · 2025Review
- Mannosamine-Modified Poly(lactic-Bioconjugate chemistry · 2025Article
- Sorafenib-Drug Delivery Strategies in Primary Liver Cancer.Journal of functional biomaterials · 2025Review
- Pooled Nanoparticle Screening Using a Chemical Barcoding Approach.Angewandte Chemie (International ed. in English) · 2025Article
- Drug-loaded nanoparticles reduced platelet aggregation and blood coagulation.Frontiers in medical technology · 2025Article
- Cartilage-targeting peptide-modified cerium oxide nanoparticles alleviate oxidative stress and cartilage damage in osteoarthritis.Journal of nanobiotechnology · 2024Article
- Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.Advanced functional materials · 2024Article
- Visualization of microRNA therapy in cancers delivered by small extracellular vesicles.Journal of nanobiotechnology · 2023Article
- Liposomal nanocarriers of preassembled glycocalyx expeditiously restore endothelial glycocalyx in endotoxemia.American journal of physiology. Heart and circulatory physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The liver is a major barrier for site-specific delivery of systemically injected nanoparticles, as up to 90% of the dose is usually captured by this organ. Kupffer cells are thought to be the main cellular component responsible for nanoparticle accumulation in the liver. These resident macrophages form part of the mononuclear phagocyte system, which recognizes and engulfs foreign bodies in the circulatory system. In this study, we have compared two strategies for reducing nanoparticle accumulation in the liver, in order to investigate the specific contribution of Kupffer cells. Specifically, we have performed a comparison of the capability of pegylation and Kupffer cell depletion to reduce liposome accumulation in the liver. Pegylation reduces nanoparticle interactions with all types of cells and can serve as a control for elucidating the role of specific cell populations in liver accumulation. The results indicate that liposome pegylation is a more effective strategy for avoiding liver uptake compared to depletion of Kupffer cells, suggesting that nanoparticle interactions with other cells in the liver may also play a contributing role. This study highlights the need for a more complete understanding of factors that mediate nanoparticle accumulation in the liver and for the exploration of microenvironmental modulation strategies for reducing nanoparticle-cell interactions in this organ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.